Evaluation of Atorvastatin Treatment on Carotid Plaque.

Back to Search
Print
Bookmark Trial

NCT00343655

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Boston, Massachusetts, 02114, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cardiovascular Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with measurable carotid plaque with lipid and are eligible for statin therapy.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects at higher risk for cardiovascular disease with a screen LDL-cholesterol
greater than 120 mg/dL,


- Subjects currently on high dose statin, and


- Subjects with contraindications for MRI or statin therapy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Cardiovascular DiseasesAtorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
NCT00159835
  1. Arhus C,
  2. Copenhagen,
  3. Esbjerg,
  4. Fredericia,
  5. Frederiksberg,
  6. Frederikssund,
  7. Grena,
  8. Helsingoer,
  9. Hjorring,
  10. Holbak,
  11. Holstebro,
  12. Hvidovre,
  13. Kabenhavn S,
  14. Kalundborg,
  15. Kobenhavn K,
  16. Kobenhavn Nv,
  17. Koge,
  18. København NV,
  19. Middelfart,
  20. Naestved,
  21. Nykobing F,
  22. Odder,
  23. Randers,
  24. Roskilde,
  25. Silkeborg,
  26. Skive,
  27. Slagelse,
  28. Svendborg,
  29. Heinola,
  30. Helsinki,
  31. Helsinki,
  32. Joensuu,
  33. Jyvaskyla,
  34. Kerava,
  35. Kuopio,
  36. Lahti,
  37. Lappeenranta,
  38. Lohja,
  39. Mikkeli,
  40. Rauma,
  41. Salo,
  42. Siaraalamaki,
  43. Tammisaari,
  44. Tampere,
  45. Vantaa,
  46. Reykjavik,
  47. Reykjavik,
  48. 's-Hertogenbosch,
  49. Alkmaar,
  50. Amsterdam,
  51. Assen,
  52. Breda,
  53. Capelle Aan Den Ijssel,
  54. Delft,
  55. Deventer,
  56. EDE,
  57. Eindhoven,
  58. Enschede,
  59. Goes,
  60. Groningen,
  61. Hoorn,
  62. Nijmegen,
  63. Oss,
  64. Rotterdam,
  65. Tilburg,
  66. Tilurg,
  67. Utrecht,
  68. Weert,
  69. Zwijndrecht,
  70. Zwolle,
  71. Alesund,
  72. Alesund,
  73. Bergen,
  74. Bergen,
  75. Bergen,
  76. Bergen,
  77. Bergen,
  78. Bodo,
  79. Flekkefjord,
  80. Forde,
  81. Hammerfest,
  82. Haugesund,
  83. Hobøl,
  84. Jessheim,
  85. Karasjok,
  86. Kongsberg,
  87. Kongsvinger,
  88. Kragero,
  89. Kristiansand,
  90. Kristiansund N,
  91. Larvik,
  92. Levanger,
  93. Lillestom,
  94. Lorenskog,
  95. Mo I Rana,
  96. Molde,
  97. Molde,
  98. Mosjøen,
  99. Moss,
  100. Mysen,
  101. Nesttun,
  102. Notodden,
  103. Odda,
  104. Oslo,
  105. Oslo,
  106. Oslo,
  107. Oslo,
  108. Oslo,
  109. Oslo,
  110. Oslo,
  111. Oslo,
  112. Paradis,
  113. Porsgrunn,
  114. Rud,
  115. Sandvika,
  116. Skedsmokorset,
  117. Ski,
  118. Stavanger,
  119. Stavanger,
  120. Stavanger,
  121. Stavanger,
  122. Stord,
  123. Tansberg,
  124. Tonsberg,
  125. Trondheim,
  126. Trondheim,
  127. Tynset,
  128. Volda,
  129. Alingsas,
  130. Angelholm,
  131. Balsta,
  132. Boras,
  133. Eksjo,
  134. Eskilstuna,
  135. Fagersta,
  136. Falkoping,
  137. Falun,
  138. Finspang,
  139. Gateborg,
  140. Gavle,
  141. Gavle,
  142. Gavle,
  143. Gavle,
  144. Goteborg,
  145. Gothenburg,
  146. Grastorp,
  147. Halmstad,
  148. Hassleholm,
  149. Hassleholm,
  150. Helsingborg,
  151. Helsingborg,
  152. Hudiksvall,
  153. Jonkoping,
  154. Kalmar,
  155. Karlshamn,
  156. Karlskoga,
  157. Karlskrona,
  158. Karlstad,
  159. Katarineholm,
  160. Koping,
  161. Kristinehamn,
  162. Lidkoping,
  163. Linka Ping,
  164. Ljungby,
  165. Ludvika,
  166. Lulea,
  167. Lycksele,
  168. Malmo,
  169. Malmo,
  170. Malmo,
  171. Malmo,
  172. Mariestad,
  173. Molndal,
  174. Motala,
  175. Norrkoping,
  176. Sala,
  177. Sandviken,
  178. Skelleftea,
  179. Skene,
  180. Skovde,
  181. Sodertalje,
  182. Stockholm,
  183. Stockholm,
  184. Stockholm,
  185. Stockholm,
  186. Stockholm,
  187. Stockholm,
  188. Stromstad,
  189. Uddevalla,
  190. Umea,
  191. Varberg,
  192. Vastervik,
  193. Vänersborg,
ALL GENDERS
0+
years
MULTIPLE SITES
Cardiovascular DiseasesEvaluation of Atorvastatin Treatment on Carotid Plaque.
NCT00343655
  1. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Evaluation of Atorvastatin Treatment on Carotid Plaque.
Official Title  ICMJE A Randomized Clinical Trial Of Atorvastatin 10 Mg And 80 Mg In The Reversal Of Or Stabilization Of Carotid Atheroma Lipid Pool
Brief Summary The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the plaque in patients.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Cardiovascular Diseases
Intervention  ICMJE Drug: Atorvastatin
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: June 20, 2006)		160
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects with measurable carotid plaque with lipid and are eligible for statin therapy.

Exclusion Criteria:

  • Subjects at higher risk for cardiovascular disease with a screen LDL-cholesterol greater than 120 mg/dL,
  • Subjects currently on high dose statin, and
  • Subjects with contraindications for MRI or statin therapy.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00343655
Other Study ID Numbers  ICMJE A2581152
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP